The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study
Patients receiving combination therapy with metformin and SGLT2 inhibitors showed significantly reduced risks of kidney disease progression and mortality compared to those treated with SGLT2 inhibitors alone. These findings support the use of metformin with SGLT2 inhibitors as a first-line treatment strategy for type 2 diabetes irrespective of glycemic control or cardio-renal risk factors.
Authors
- Eviatar Nesher (ORCID: https://orcid.org/0000-0002-8753-2688)
- Timna Agur (ORCID: https://orcid.org/0000-0001-8263-0900)
- Benaya Rozen‐Zvi
- Shira Goldman (ORCID: https://orcid.org/0000-0001-7011-5872)
- Ittai Fattal
- Борис Зингерман (ORCID: https://orcid.org/0000-0002-1855-1834)
- Dana Bielopolski (ORCID: https://orcid.org/0000-0001-9476-0032)
- Eshcar Meisel (ORCID: https://orcid.org/0000-0003-3142-8600)
- Tali Steinmetz (ORCID: https://orcid.org/0000-0002-5377-9156)
Institutions
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1186/s12933-025-02643-6
- Citations
- 13
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 16.83